STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.

ABSTRACT:

Objective

Improvements to bladder cancer risk stratification guidelines are needed to better tailor post-operative surveillance and adjuvant therapy to individual patients. We previously identified STAG2 as a commonly mutated tumor suppressor gene in bladder cancer and an independent predictor of progression in NMIBC. Here we test the value of combining STAG2 immunostaining with other risk stratification biomarkers in NMIBC, and as an individual biomarker in MIBC.

Materials and methods

STAG2 immunohistochemistry was performed on a progressor-enriched cohort of tumors from 297 patients with NMIBC, and on tumors from 406 patients with MIBC from Aarhus University Hospital in Denmark. Survival analysis was performed using Kaplan-Meier survival analysis, the log rank test, and Co

SUBMITTER: Taber A 

PROVIDER: S-EPMC8286298 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature